Certain factors may contribute to higher occurrences of non-melanoma skin cancer in these patients, according to a novel systemic review.
Health Professionals
Predictive tool for melanoma could guide immunotherapy choices
Summary: In previous research, Dana-Farber researchers found that a tumor’s genomic heterogeneity, meaning the tumor’s propensity to develop new mutations, and low genomic ploidy, a measure of the number of chromosomes in the cells, predicts resistance to immune checkpoint blockade with anti-PD-1 therapy.
10-Year Survival Rates Near 80% for Melanoma Patients Responding to Checkpoint Inhibitors
Two sets of 10-year outcome data from large multicenter trials with checkpoint inhibitors for the treatment of advanced melanoma found that more than 40% of treated patients survive 10 years overall, but the 10-year melanoma-free survival approaches 100% in those with a deep response who remain in progression-free survival (PFS) at three years.
HBI-8000 Plus Nivolumab Is Safe, Active in Melanoma
The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no prior anti–PD-1/PD-L1 treatment.